COVID-19: a short message to rheumatologists

Piotr Leszczyński

Konferencja Pacjent post-COVID-owy. Co...

Pobierz cytowanie

COVID-19: a short message to rheumatologists

Piotr Leszczyński ^1,2

Więcej

Ukryj

Department of Rheumatology and Rehabilitation, Poznań University of Medical Sciences, Poland

Department of Rheumatology and Osteoporosis, Józef Struś Memorial Multidisciplinary Municipal Hospital in Poznań, Poland

Data publikacji online: 08-09-2021

Reumatologia 2021;(Konferencja Pacjent post-COVID-owy. Co zostaje, a co się zmienia? 1):130-133

Artykuł (PDF)

Referencje (13)

STRESZCZENIE

For several months, SARS-CoV-2 virus infection, which sometimes causes critical COVID-19 disease primarily with lung involvement, has been the one and only medical and scientific topic. The widespread occurrence of this type of coronavirus has led to a global pandemic and a huge social confusion that has had and will have a significant impact on our lives.
From the point of view of a specialist in rheumatology and internal medicine, currently performing duties of a medical doctor of infectious diseases in the department of rheumatology in a temporarily uniform hospital in Poznań, Poland, various questions and reflections arise.

REFERENCJE (13)

Savarino A, Boelaert JR, Cassone A, et. al. Effects of Chloroquine on Viral Infections: An Old Drug Against Today’s Diseases? Lancet Infect Dis 2002, 3: 722-727, DOI: 10.1016/s1473-3099(03)00806-5.

CrossRef

Google Scholar

Wolfram J, Nizzero S, Liu H, et al. A Chloroquine-Induced Macrophage-Preconditioning Strategy for Improved Nanodelivery. Sci Rep 2017, 7: 13738, DOI: 10.1038/s41598-017-14221-2.

CrossRef

Google Scholar

Hu YT, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020: 1-3, DOI: 10.1038/s41565-020-0674-9 [Epub ahead of print].

Google Scholar

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. 2020, https://doi.org/10.1016/ S0140-6736(20)31180-6.

Google Scholar

Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395: e30-e31, DOI: 10.1016/S0140-6736(20)30304-4.

CrossRef

Google Scholar

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020 (in press), DOI: 10.1016/j.cell.2020.02.052.

CrossRef

Google Scholar

Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 2020, 202003.00026.

Google Scholar

SIMIT – Societa` Italiana di Malattie Infettive e Tropicali – Sezione Regione Lombardia. Vademecum per la cura delle persone con malattia da COVI-19. Edizione 2.0, 13 marzo 2020. http://www.simit.org/medias/15...- vademecum-13-03-202.pdf.

Google Scholar

Sönmez HE, Demir S, Bilginer Y, Özen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol 2018; 37: 3329-3335, DOI: 10.1007/s10067-018-4095-1.

CrossRef

Google Scholar

10.

Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 2020; 38: 175-180.

Google Scholar

11.

Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; pii: annrheumdis-2020-217424, DOI: 10.1136/annrheumdis-2020-217424 [Epub ahead of print].

CrossRef

Google Scholar

12.

Covid-19 in Immune-Mediated Inflammatory Diseases – Case Series from New York. Downloaded from nejm.org on May 10, 2020, DOI: 10.1056/NEJMc2009567.

CrossRef

Google Scholar

13.

https://www.eular.org/myUpload....

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Wyślij swój artykuł

Archiwum

Dla autorów

Udostępnij

Wyślij mailem

Indeksy

Indeks słów kluczowych

Indeks dziedzin

Indeks autorów

eISSN:	2084-9834
ISSN:	0034-6233